BASi Appoints Joe Flynn as Chief Commercial Officer
February 21 2019 - 9:23AM
Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the
“Company”) is pleased to announce that Joe Flynn has been appointed
as Chief Commercial Officer of the Company, effective as of
February 21, 2019. Mr. Flynn will be responsible for leading sales
and marketing efforts across BASi’s three sites located in West
Lafayette and Evansville, Indiana, and St. Louis, Missouri.
Mr. Flynn has an esteemed career as a senior
executive in contract research, with over 25 years of strategic and
operational experience focusing on pharmaceutical research and
development. Most recently, he served as Chief Commercial Officer
and Executive Vice President of Seventh Wave Laboratories. Mr.
Flynn joined BASi in July of last year when BASi acquired the
operations of Seventh Wave in order to provide broader solutions
and greater scientific expertise to its clients.
“I have great confidence in Joe and his ability
to shape our commercial engine,” said Robert Leasure, Jr., BASi’s
President and Chief Executive Officer. “The team Joe has in place
is solidly positioned to help drive our internal growth objectives
and support any external opportunities we have in the future. Joe
will play a vital role on our leadership team and brings a valuable
combination of laboratory experience, industry knowledge, and
commercial leadership. His appointment fills one more critical
position towards our Company’s growth and ability to support our
clients.”
Prior to his tenure at Seventh Wave
Laboratories, Mr. Flynn was a global vice president of sales and
client services for multiple divisions of Covance Laboratories.
Prior to Covance, he held operational roles at PPD Inc. and ABC
Laboratories (now Eurofins). Mr. Flynn began his career with a BS
in Biochemistry from the University of Missouri, Columbia.
“I am enthusiastic about the opportunities
before us, and proud to be a part of this team. Our position—being
small enough to be responsive but big enough to deliver—is already
resonating with clients. We have good momentum and are building
backlog and serving our loyal clients, while layering in new
clients every day. With modest enhancements to our commercial
engine, we have a great opportunity to differentiate our integrated
offerings and help our clients exceed their goals.”
About Bioanalytical Systems,
Inc.
BASi is a pharmaceutical development company
providing contract research services and monitoring instruments to
emerging pharmaceutical companies and the world's leading drug
development companies and medical research organizations. The
Company focuses on developing innovative services supporting its
clients’ discovery and development objectives for improved
decision-making and accelerated goal attainment. BASi’s products
focus on increasing efficiency, improving data, and reducing the
cost of taking new drugs to market.
Visit www.BASinc.com for more information about BASi.
This release may contain forward-looking
statements that are subject to risks and uncertainties including,
but not limited to, risks and uncertainties related to changes in
the market and demand for our products and services, the
development, marketing and sales of products and services, changes
in technology, industry and regulatory standards, and various
market and operating risks detailed in the company's filings with
the U.S. Securities and Exchange Commission.
Company Contact:Jill C.
BlumhoffChief Financial OfficerPhone:
756.497.8381jblumhoff@BASinc.com
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Sep 2023 to Sep 2024